Outcome for survivors of meningococcal B disease generally good

posted 13 Oct 2012, 12:36 by Damian Wood   [ updated 13 Oct 2012, 12:37 ]
The MOSAIC case control study published in the Lancet Neurology recruited children from the UK National Meningococcal Registry between May, 2008, and September, 2010. Survivors of serogroup B meningococcal disease aged 1 month to 13 years at disease were compared to matched controls for physical, psychological, neurocognitive, and educational outcomes. The researchers showed that most children survive serogroup B meningococcal disease without major sequelae. However, about a tenth have major disabling deficits and more than a third have one or more deficits in physical, cognitive, and psychological functioning, with the additional burden of memory deficits and executive function problems. They hope their findings will not only help to guide assessments of new vaccines but they go on to suggest all survivors of serogroup B meningococcal disease should be screened for psychological disorders and cognitive deficits in addition to hearing loss.